Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin A1c values

Detalhes bibliográficos
Autor(a) principal: Woerle, Hans J.
Data de Publicação: 2004
Outros Autores: Pimenta, Walkyria P., Meyer, Christian, Gosmanov, Niyaz R., Szoke, Ervin, Szombathy, Tamas, Mitrakou, Asimina, Gerich, John E.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://dx.doi.org/10.1001/archinte.164.15.1627
http://hdl.handle.net/11449/219435
Resumo: Background: Increased fasting plasma glucose (FPG) and 2-hour postchallenge plasma glucose (PCPG) levels with normal hemoglobin A1c (HbA 1c) levels are recognized as risk factors for cardiovascular disease. We undertook this study to determine the relationships between FPG and 2-hour PCPG levels over the normal HbA1c range and to assess the need to control FPG and 2-hour PCPG levels to achieve HbA1c targets recommended by the American Diabetes Association (ADA), International Diabetes Federation (IDF), and American College of Endocrinology (ACE). Methods: The data of all healthy individuals with HbA1c values less than 7.0% (N=457) who underwent oral glucose tolerance tests between 1986 and 2002 for either screening as potential research volunteers (93%) or diagnostic purposes (7%) were analyzed. Results: Of 404 individuals with normal HbA1c levels (<6.0%), 60% had normal glucose tolerance, 33% had impaired glucose tolerance, 1% had isolated impaired FPG, and 6% had type 2 diabetes mellitus. Of 161 individuals without normal glucose tolerance, 80% had normal FPG levels. Both FPG and 2-hour PCPG levels increased as HbA1c increased and were significantly correlated (r=0.63, P<.001), but the 2-hour PCPG level increased at a rate 4 times greater than FPG and accounted for a greater proportion of HbA1c. People who met the IDF and ACE HbA1c targets (<6.5%) had significantly lower 2-hour PCPG levels than those who met the ADA target (<7.0%) (P=.03), whereas FPG levels were similar. Conclusions: Most individuals with HbA1c values between 6.0% and 7.0% have normal FPG levels but abnormal 2-hour PCPG levels, suggesting that an upper limit of normal for FPG at 110 mg/dL (6.11 mmol/L) is too high and that attempts to lower HbA1c in these individuals will require treatment preferentially directed at lowering postprandial glucose levels.
id UNSP_b812b36f82357587763d630a62c4987a
oai_identifier_str oai:repositorio.unesp.br:11449/219435
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin A1c valuesBackground: Increased fasting plasma glucose (FPG) and 2-hour postchallenge plasma glucose (PCPG) levels with normal hemoglobin A1c (HbA 1c) levels are recognized as risk factors for cardiovascular disease. We undertook this study to determine the relationships between FPG and 2-hour PCPG levels over the normal HbA1c range and to assess the need to control FPG and 2-hour PCPG levels to achieve HbA1c targets recommended by the American Diabetes Association (ADA), International Diabetes Federation (IDF), and American College of Endocrinology (ACE). Methods: The data of all healthy individuals with HbA1c values less than 7.0% (N=457) who underwent oral glucose tolerance tests between 1986 and 2002 for either screening as potential research volunteers (93%) or diagnostic purposes (7%) were analyzed. Results: Of 404 individuals with normal HbA1c levels (<6.0%), 60% had normal glucose tolerance, 33% had impaired glucose tolerance, 1% had isolated impaired FPG, and 6% had type 2 diabetes mellitus. Of 161 individuals without normal glucose tolerance, 80% had normal FPG levels. Both FPG and 2-hour PCPG levels increased as HbA1c increased and were significantly correlated (r=0.63, P<.001), but the 2-hour PCPG level increased at a rate 4 times greater than FPG and accounted for a greater proportion of HbA1c. People who met the IDF and ACE HbA1c targets (<6.5%) had significantly lower 2-hour PCPG levels than those who met the ADA target (<7.0%) (P=.03), whereas FPG levels were similar. Conclusions: Most individuals with HbA1c values between 6.0% and 7.0% have normal FPG levels but abnormal 2-hour PCPG levels, suggesting that an upper limit of normal for FPG at 110 mg/dL (6.11 mmol/L) is too high and that attempts to lower HbA1c in these individuals will require treatment preferentially directed at lowering postprandial glucose levels.Department of Medicine Univ. of Rochester Sch. of Medicine, Rochester, NYDepartment of Clinical Medicine Faculdade de Medicina Botucatu University of São Paulo State, São PauloDiabetes-Metabolism Unit Henry Dunant Hospital, AthensDepartment of Internal Medicine II Ludwig-Maximilians-Univ. of Munich, MunichDept. of Endocrinol. and Metabolism Carl T. Hayden Vet. Aff. Med. Center, Phoenix, AZDepartment of Medicine Unity Health SystemDepartment of Medicine Univ. of Rochester Sch. of Medicine Campus Box MED/CRC, 601 Elmwood Ave, Rochester, NY 14642Univ. of Rochester Sch. of MedicineUniversidade de São Paulo (USP)Henry Dunant HospitalLudwig-Maximilians-Univ. of MunichCarl T. Hayden Vet. Aff. Med. CenterUnity Health SystemWoerle, Hans J.Pimenta, Walkyria P.Meyer, ChristianGosmanov, Niyaz R.Szoke, ErvinSzombathy, TamasMitrakou, AsiminaGerich, John E.2022-04-28T18:55:37Z2022-04-28T18:55:37Z2004-08-09info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article1627-1632http://dx.doi.org/10.1001/archinte.164.15.1627Archives of Internal Medicine, v. 164, n. 15, p. 1627-1632, 2004.0003-9926http://hdl.handle.net/11449/21943510.1001/archinte.164.15.16272-s2.0-3843091626Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengArchives of Internal Medicineinfo:eu-repo/semantics/openAccess2022-04-28T18:55:37Zoai:repositorio.unesp.br:11449/219435Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-05T19:30:37.073453Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin A1c values
title Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin A1c values
spellingShingle Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin A1c values
Woerle, Hans J.
title_short Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin A1c values
title_full Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin A1c values
title_fullStr Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin A1c values
title_full_unstemmed Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin A1c values
title_sort Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin A1c values
author Woerle, Hans J.
author_facet Woerle, Hans J.
Pimenta, Walkyria P.
Meyer, Christian
Gosmanov, Niyaz R.
Szoke, Ervin
Szombathy, Tamas
Mitrakou, Asimina
Gerich, John E.
author_role author
author2 Pimenta, Walkyria P.
Meyer, Christian
Gosmanov, Niyaz R.
Szoke, Ervin
Szombathy, Tamas
Mitrakou, Asimina
Gerich, John E.
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Univ. of Rochester Sch. of Medicine
Universidade de São Paulo (USP)
Henry Dunant Hospital
Ludwig-Maximilians-Univ. of Munich
Carl T. Hayden Vet. Aff. Med. Center
Unity Health System
dc.contributor.author.fl_str_mv Woerle, Hans J.
Pimenta, Walkyria P.
Meyer, Christian
Gosmanov, Niyaz R.
Szoke, Ervin
Szombathy, Tamas
Mitrakou, Asimina
Gerich, John E.
description Background: Increased fasting plasma glucose (FPG) and 2-hour postchallenge plasma glucose (PCPG) levels with normal hemoglobin A1c (HbA 1c) levels are recognized as risk factors for cardiovascular disease. We undertook this study to determine the relationships between FPG and 2-hour PCPG levels over the normal HbA1c range and to assess the need to control FPG and 2-hour PCPG levels to achieve HbA1c targets recommended by the American Diabetes Association (ADA), International Diabetes Federation (IDF), and American College of Endocrinology (ACE). Methods: The data of all healthy individuals with HbA1c values less than 7.0% (N=457) who underwent oral glucose tolerance tests between 1986 and 2002 for either screening as potential research volunteers (93%) or diagnostic purposes (7%) were analyzed. Results: Of 404 individuals with normal HbA1c levels (<6.0%), 60% had normal glucose tolerance, 33% had impaired glucose tolerance, 1% had isolated impaired FPG, and 6% had type 2 diabetes mellitus. Of 161 individuals without normal glucose tolerance, 80% had normal FPG levels. Both FPG and 2-hour PCPG levels increased as HbA1c increased and were significantly correlated (r=0.63, P<.001), but the 2-hour PCPG level increased at a rate 4 times greater than FPG and accounted for a greater proportion of HbA1c. People who met the IDF and ACE HbA1c targets (<6.5%) had significantly lower 2-hour PCPG levels than those who met the ADA target (<7.0%) (P=.03), whereas FPG levels were similar. Conclusions: Most individuals with HbA1c values between 6.0% and 7.0% have normal FPG levels but abnormal 2-hour PCPG levels, suggesting that an upper limit of normal for FPG at 110 mg/dL (6.11 mmol/L) is too high and that attempts to lower HbA1c in these individuals will require treatment preferentially directed at lowering postprandial glucose levels.
publishDate 2004
dc.date.none.fl_str_mv 2004-08-09
2022-04-28T18:55:37Z
2022-04-28T18:55:37Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1001/archinte.164.15.1627
Archives of Internal Medicine, v. 164, n. 15, p. 1627-1632, 2004.
0003-9926
http://hdl.handle.net/11449/219435
10.1001/archinte.164.15.1627
2-s2.0-3843091626
url http://dx.doi.org/10.1001/archinte.164.15.1627
http://hdl.handle.net/11449/219435
identifier_str_mv Archives of Internal Medicine, v. 164, n. 15, p. 1627-1632, 2004.
0003-9926
10.1001/archinte.164.15.1627
2-s2.0-3843091626
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Archives of Internal Medicine
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 1627-1632
dc.source.none.fl_str_mv Scopus
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv
_version_ 1808129079367434240